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Introduction
Early diagnosis and treatment can considerably improve the 
prognosis of serious medical conditions. One of the non-
invasive methods of detecting possible early disease, and the 
need for further investigation, is the measurement of markers 
in exhaled air by mass spectrometry. However, the equip-
ment for this technique is large, expensive and fixed. Now, a 
smaller, less expensive portable quadrupole mass spectrom-
eter (QMS) system has been developed which could be uti-
lised at more health service locations. Before this portable 
QMS can be used with confidence, it is necessary to measure 
its performance in a clinical setting against a currently used 
mass spectrometer technique.
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Abstract
Context: In the non-invasive detection of markers of disease, mass spectrometry is able to detect small quantities of volatile 
markers in exhaled air. However, the problem of size, expense and immobility of conventional mass spectrometry equipment 
has restricted its use. Now, a smaller, less expensive, portable quadrupole mass spectrometer system has been developed. 
Helicobacter pylori has been implicated in the development of chronic gastritis, gastric and duodenal ulcers and gastric cancer.
Objectives: To compare the results obtained from the presence of H. pylori by a carbon-13 urea test using a portable 
quadrupole mass spectrometer system with those from a fixed mass spectrometer in a hospital-based clinical trial.
Methods: Following ethical approval, 45 patients attending a gastroenterology clinic at the Royal Liverpool University 
Hospital exhaled a breath sample into a Tedlar gas sampling bag. They then drank an orange juice containing urea radiolabelled 
with carbon and 30 min later gave a second breath sample. The carbon-13 content of both samples was measured using 
both quadrupole mass spectrometer systems. If the post-drink level exceeded the pre-drink level by 3% or more, a positive 
diagnosis for the presence of H. pylori was made.
Results: The findings were compared to the results using conventional isotope ratio mass spectrometry using a laboratory-
based magnetic sector instrument off-site. The results showed agreement in 39 of the 45 patients.
Conclusions: This study suggests that a portable quadrupole mass spectrometer is a potential alternative to the conventional 
centralised testing equipment. Future development of the portable quadrupole mass spectrometer to reduce further its size 
and cost is indicated, together with further work to validate this new equipment and to enhance its use in mass spectrometry 
diagnosis of other medical conditions.
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A clinically important early detection is the Helicobacter 
pylori infection of the stomach. H. pylori has an important role 
in the development of active chronic gastritis and gastric and 
duodenal ulcers1–4 and of gastric cancer.5 The World Health 
Organization’s International Agency for Research on Cancer 
classifies the bacterium as a grade 1 carcinogen.6 H. pylori 
secretes the enzyme urease, converting urea into ammonia and 
bicarbonate. Of the various available tests for the H. pylori 
infection, carbon-13 and carbon-14 urea breath tests are well 
established and have the advantages of being rapid, non-inva-
sive and having high sensitivity and specificity.7–10
Therefore, the aim of this study was to compare the results 
obtained for the presence or absence of H. pylori by a carbon-13 
urea breath test using the portable QMS system with those from 
a fixed mass spectrometer in a hospital-based clinical trial.
Patients and method
Patients
Ethical approval for the study was obtained from the Royal 
Liverpool and Broadgreen University Hospitals Trust Ethics 
Committee. In all, 45 patients aged 30–60 years attending the 
Gastroenterology Department of the Royal Liverpool 
University Hospital, with upper gastrointestinal symptoms 
and suspected of having H. pylori colonisation of the stom-
ach, gave written informed consent to participate in the study.
The clinical procedure for each patient was that an initial 
breath sample was taken as a baseline. The patient then drank 
100 mL of unsweetened orange juice containing 75 mg of 
C13 urea. Thirty minutes later, a second breath sample was 
taken. The breath samples were gathered in Tedlar gas sam-
ple bags, size 25 × 22.5 cm2.11
Analysis of breath samples
A portable QMS system (Figure 1) with a triple filter, 
closed ion source and heated capillary inlet (MK2 Cirrus) 
was used to measure carbon-13 levels in the breath sam-
ples in the Tedlar bags.11–13 The bag was connected to the 
open value of the QMS and sampled for 10 s to ensure uni-
form flow. The QMS sampling programme utilised six 
consecutive scans.
The diagnosis made using the portable QMS was com-
pared with the diagnosis made in the usual manner by send-
ing patient breath samples to a central off-site isotope ratio 
mass spectrometry (IRMS) facility.
Analysis of results
The measurements obtained were averaged and recorded. 
The percentage change in C13 content was obtained from 
mass spectra using a MATLAB programme. Figure 2 shows 
the output with a log scale and spectral at m/z 44 and 45. The 
pre-drink and post-drink measurements were used to deter-
mine the presence or absence of H. pylori.
Figure 3 shows the readings for one patient with pre-drink 
and post-drink findings superimposed to illustrate the differ-
ences between the two sets of readings. As the post-drink 
Figure 1. Schematic diagram of the portable QMS and vacuum 
system.
Figure 2. QMS output from patient breath with a log scale showing spectral peaks at m/z 44 and 45 corresponding to 12CO2 and 13CO2.
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reading was more than 3% greater than the pre-drink read-
ing, a positive diagnosis was made.
Figure 4 shows the readings for another patient where the 
ratio of the peak heights for m/z = 44 and m/z 45 remained 
unchanged after the urea-containing drink. This led to a neg-
ative diagnosis, that is, the absence of H. pylori.
A receiver operating characteristic (ROC) plot (Figure 5) 
was constructed for the portable QMS results compared with 
the conventional findings.
Results
The test methodology was found to be straightforward to use 
and gave a rapid result. The portable QMS equipment and the 
Tedlar bags were used without any problems. The results of the 
45 patients are summarised in Table 1. For 39 of the 45 patients, 
the results using the portable QMS were the same as the con-
ventional IRMS results; there were three false positives 
(patients 7, 9 and 25) and three false negatives (patients 17, 21 
and 42) giving an overall agreement of 87%. In the ROC plot, 
the curves were constructed by computing the sensitivity and 
specificity of the clinical findings in predicting the presence or 
absence of H. pylori. The area under the curve is 0.71, grading 
the accuracy of the carbon-13 urea breath test as ‘fair’.
Discussion
The value of early diagnosis to enhance treatment outcomes 
is well demonstrated in the case of infection with H. pylori. 
If the infection becomes chronic, debilitating illness from 
gastric and duodenal ulceration and gastric cancer can fol-
low,5 yet curative treatment at the appropriate stage may 
require only outpatient medication.
The carbon-13 urea breath test is rapid and non-invasive, 
while having good sensitivity and specificity which have 
been shown to range from 90% to 100% in comparison with 
Figure 3. Patient 4. The pre-drink and post-drink breath samples superimposed; lighter shading is post-drink sample. The difference 
between the samples suggests a positive diagnosis.
Figure 4. The pre-drink and post-drink breath samples superimposed; the lighter shading is the post-drink sample. The lack of 
difference between samples suggests a negative diagnosis.
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Table 1. Summary results for 45 patients.
Patient Percentage 
change
Portable 
result
Hospital 
result
1 2.3805 Negative Negative
2 2.6119 Negative Negative
3 −0.27153 Negative Negative
4 3.3088 Positive Positive
5 1.5157 Negative Negative
6 −0.41268 Negative Negative
7 3.2864 Positive Negative
8 −0.6307 Negative Negative
9 5.0282 Positive Negative
10 −1.4281 Negative Negative
11 −1.3585 Negative Negative
12 −1.392 Negative Negative
13 1.7658 Negative Negative
14 −7.4317 Negative Negative
15 −5.7499 Negative Negative
16 −5.5067 Negative Negative
17 −1.7904 Negative Positive
18 −1.3738 Negative Negative
19 2.7059 Negative Negative
20 0.90435 Negative Negative
21 0.057905 Negative Positive
22 −6.1336 Negative Negative
23 1.2009 Negative Negative
24 0.33432 Negative Negative
25 3.2398 Positive Negative
26 1.4659 Negative Negative
27 2.0393 Negative Negative
28 −3.0747 Negative Negative
29 −3.1673 Negative Negative
30 0.42858 Negative Negative
31 −0.22003 Negative Negative
32 −0.130014 Negative Negative
33 −1.3796 Negative Negative
34 5.2481 Positive Positive
35 2.4104 Negative Negative
36 −3.2602 Negative Negative
37 −1.4923 Negative Negative
38 −4.7456 Negative Negative
39 −6.1669 Negative Negative
40 −1.4061 Negative Negative
41 −3.7616 Negative Negative
42 0.4252 Negative Positive
43 −0.046 Negative Negative
44 −5.0121 Negative Negative
45 0 Negative Negative
biopsy-based tests.14,15 H. pylori produces a significant quan-
tity of the enzyme urease in the gastric mucosa of the infected 
individual. The ingested carbon-13 labelled urea is hydro-
lysed by the urease. Ammonia and carbon dioxide are pro-
duced, diffused into the blood and are excreted in the breath 
via the lungs.16,17 IRMS may be carried out using a variety of 
methods; one of the most popular uses gas chromatography 
combustion (GC-C) MS to ascertain the relative ratio of light 
stable isotopes of carbon (13C/12C), hydrogen (2H/1H), nitro-
gen (15N/14N) or oxygen (18O/16O). The time taken to send 
the breath samples away, process them and return the results 
to the hospital clinician can be upwards of several days.
Several methods for capturing and transporting the breath 
samples have been used, including canisters, absorbing agents 
and Teflon or Tedlar bags. The sample containers need to be 
easy to handle and able to store the sample securely for a period 
of time. Canisters are not appropriate for breath measurement 
as they need to be evacuated before sampling. Absorbing 
agents like Tenax are compound specific. Teflon bags are rela-
tively expensive and fragile, while Tedlar bags as used in this 
study are tough, durable and chemically inert to a wide range of 
compounds.11 They were found to be easy to use.
The threshold increase in the post-drink to pre-drink 
samples of 3% was chosen to allow for sampling variation 
(Figure 6). The results obtained agree reasonably well with 
the conventional QMS results (87% agreement), indicating 
that using a portable QMS is promising as a potential alterna-
tive to the expensive centralised testing facility. Even using 
different fixed IRMS machines, there are some differences in 
the results obtained. For example, in testing a large sample 
using two different conventional IRMS machines, Savarino 
et al.18 found that there was close but not complete correlation 
(r = 0.98) and sensitivity and specificity of 97%–100%. The 
ROC plot of the results provided a graphical indication of the 
performance of the test in differentiating normal and diseased 
state.
As this was a non-invasive study, and the aim was to com-
pare the new equipment with existing equipment, biopsies 
were not undertaken as part of this study. Even biopsy 
Figure 5. An ROC curve with the curves constructed by 
plotting the true-positive rate (sensitivity) against the false-
positive rate (specificity). A positive diagnosis was 3% above the 
baseline of the initial reading.
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samples do not provide 100% sensitivity and specificity of 
diagnosis for Savarino et al.18 had to exclude 9 out of 124 
patients from their study because of divergent results between 
rapid urease testing of the biopsy specimens and the 
histology.
This study was an initial clinical trial as part of an ongoing 
programme of validation and improvement of a portable 
instrument for breath testing. It was important to examine the 
use of this novel equipment in a routine clinical setting such as 
a hospital outpatient gastroenterology clinic. However, this 
did impose limitations with the breath samples being tested on 
site with the portable QMS but needing to be transported to the 
fixed QMS and read there at a later time. Moreover, the sam-
ple size was limited by the number of suitable patients attend-
ing this clinic and consenting to participate. However, with 
each patient acting as their own control, this sample was suf-
ficient for this initial clinical study. The findings of this study 
can be used for the power calculations for the sample size in 
the next, more extensive clinical study. Another limitation was 
that the nature of the gastroenterology clinic meant that the 
patients did not fast before attending. In another study, this 
reduced the sensitivity of diagnosis to 86%.18 The spread of 
the results in the scatter plot of our results (Figure 6) was com-
parable to that in the study of Hegedus et al.19 These investiga-
tions also used cut-off levels on the measured values in order 
to simplify the test and interpretation process.18
Using the portable QMS, the test was straightforward to 
perform and gave a rapid result. The one off cost of this port-
able instrument was of the order of £15,000 which could be 
reduced if multiple units were manufactured together. This is 
considerably less than a conventional IRMS fixed system 
(circa £150,000, depending on options), but still limits avail-
ability. With further instrument development, for example, the 
use of hyperbolic electrodes, an improved, miniaturised port-
able QMS with enhanced sensitivity could be constructed and 
produced at a much reduced price of circa £10,000 k. The 
reduced size and cost would enable it to be placed in large 
general medical practices, community health clinics and com-
mercial health centres. The portable equipment (Figure 1) is 
being further developed, and more extensive clinical studies 
are indicated. Further work is also necessary in calibrating the 
level at which a diagnosis is made with the portable QMS to 
increase the agreement with the established IRMS.
Conclusion
This initial study suggests that a portable QMS is a potential 
alternative to the conventional centralised testing equipment. 
Future development of the portable QMS to reduce its size and 
cost is indicated together with more extensive trials to validate 
its use and explore its application in other medical conditions.
Acknowledgements
The authors thank Dr John Marsland for his guidance in the calcula-
tion of the ROC plot.
Declaration of conflicting interests
The portable mass spectrometer used in this trial was developed by 
the Mass Spectrometry Group of the Department of Electrical 
Engineering and Electronics, University of Liverpool, UK; five 
Figure 6. A scatter plot of the result for each patient using the portable QMS. The cut-off for a positive diagnosis was 3% above 
baseline.
 at University of East Anglia on February 24, 2016smo.sagepub.comDownloaded from 
6 SAGE Open Medicine
members of this group are authors of this article. After this trial 
concluded Q-Technologies, a spin-off company of the University 
of Liverpool of which Prof S. Taylor, one of the authors, is the 
founder, director and majority shareholder, further developed the 
equipment and now offers it.
Funding
The trial was funded by the Reach Out Growth Fund of the 
University of Liverpool.
References
 1. Warren JR and Marshall BJ. Unidentified curved bacilli on 
gastric epithelium in active chronic gastritis. Lancet 1983; 
321: 1273–1275.
 2. Hopkins RJ, Girardi LS and Tuney EA. Relationship between 
Helicobacter pylori eradication and reduced duodenal and 
gastric ulcer recurrence: a review. Gastroenterology 1996; 
110(4): 1244–1252.
 3. Dowsett SA and Kowolik MJ. Oral Helicobacter pylori: can 
we stomach it? Crit Rev Oral Biol Med 2003; 14(3): 226–233.
 4. Marshall BJ. Helicobacter pylori: past, present and future. 
Keio J Med 2003; 52(2): 80–85.
 5. Marshall BJ. Helicobacter connections. ChemMedChem 2006; 
1(8): 783–802.
 6. Stratton KR, Durch JS and Lawrence RS. Vaccines for the 21st 
century: a tool for decision making. Washington, DC: The 
National Academy Press, 2000.
 7. Ricci C, Holton J and Vaira D. Diagnosis of Helicobacter 
pylori: invasive and non-invasive tests. Best Pract Res Clin 
Gastroenterol 2007; 21(2): 299–313.
 8. Atherton JC and Spiller RC. The urea breath test for 
Helicobacter pylori. Gut 1994; 35: 723–725.
 9. Peeters M. Urea breath test: a diagnostic tool in the manage-
ment of Helicobacter pylori-related gastrointestinal diseases. 
Acta Gastroenterol Belg 1998; 61(3): 332–335.
 10. Logan RPH. Urea breath tests in the management of 
Helicobacter pylori infection. Gut 1998; 43(Suppl. 1): 
47–50.
 11. Steeghs MML, Cristescu SM and Harren FJM. The suitabil-
ity of Tedlar bags for breath sampling in medical diagnostic 
research. Physiol Meas 2007; 28(1): 73–84.
 12. Dawson PH. Principles of operation. In: Dawson PH 
(ed.) Quadrupole mass spectrometry and its applications. 
Amsterdam: Elsevier, 1976, pp.9–64.
 13. http://www.mksinst.com/product/product.aspx?ProductID=195
 14. Cutter AF, Havstad S, Ma CK, et al. Accuracy of invasive and 
non-invasive tests to diagnose Helicobacter pylori infection. 
Gastroenterology 1995; 109: 136–141.
 15. Goddard AF and Logan RPH. Review article: urea breath tests 
for detecting Helicobacter pylori. Aliment Pharmacol Ther 
1997; 11: 641–649.
 16. Dore SP, Krupadas S, Borgonha S, et al. The 13c urea breath 
test to assess Helicobacter pylori infection in school children. 
Natl Med J India 1997; 10(2): 57–60.
 17. Kolesnikov T and Lee A. Clinical infectious diseases 
– Helicobacter pylori. Bailliere Tindall 1997; 4(3): 
239–244.
 18. Savarino V, Mela GS, Zentillin P, et al. Comparison of iso-
tope ratio mass spectrometry and nondispersive isotope-
selective infrared spectroscopy for 13C-urea breath test. Am J 
Gastroenterol 1999; 94: 1203–1208.
 19. Hegedus O, Ryden J, Rehnberg AS, et al. Validated accuracy 
of a novel urea breath test for rapid Helicobacter pylori detec-
tion and in office analysis. Eur J Gastroenterol Hepatol 2002; 
14: 1–8.
 at University of East Anglia on February 24, 2016smo.sagepub.comDownloaded from 
